Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer
· seekingalpha.com
Karyopharm stock plunges after Xpovio missed phase 3 endometrial cancer goal. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...